Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 2,374 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Function Clear all
Recruiting Not applicable Interventional

Pilot Study of Neurofeedback for Photosensitivity in Mild Traumatic Brain Injury

NCT06109909
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Photophobia
Interventions
Micro Current Neurofeedback Device using Low-Frequency Pulse-Based Transcranial Electrical Stimulation
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 23, 2026, 6:59 AM EDT
Recruiting No phase listed Observational

Modifiable Variables in Parkinsonism (MVP)

NCT02194816
View directory record Official record
Conditions
Parkinson's Disease, Parkinsonism, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, Shy-Drager Syndrome, Corticobasal Degeneration, Dementia With Lewy Bodies, Pick Disease, Olivopontocerebellar Atrophies
Interventions
Not listed
Lead sponsor
Bastyr University
Other
Eligibility
19 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2030
U.S. locations
1
States / cities
Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 23, 2026, 6:59 AM EDT
Withdrawn No phase listed Observational

The Effect of Omega-3 Fatty Acid Supplementation on Intraocular Pressure & Ocular Surface

NCT02295358
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 23, 2026, 6:59 AM EDT
Enrolling by invitation Not applicable Interventional

Electrostimulation Study for Ocular Graft vs. Host Disease

NCT07166848
View directory record Official record
Conditions
Chronic Ocular Graft-versus-host Disease
Interventions
Electrodes with Currents, Electrodes without Currents
Device
Lead sponsor
Zhonghui K. Luo, MD, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 6:59 AM EDT
Completed Not applicable Interventional Results available

Hydrus Microstent for Refractory Open-Angle Glaucoma

NCT03267134
View directory record Official record
Conditions
Open-angle Glaucoma
Interventions
Hydrus Microstent, Ophthalmic surgery
Device · Procedure
Lead sponsor
Ivantis, Inc.
Industry
Eligibility
45 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
Fayetteville, Arkansas • Sacramento, California • Fort Collins, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 23, 2026, 6:59 AM EDT
Completed No phase listed Observational

An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis

NCT01863238
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ophthalmologic examinations, Ivacaftor Exposed
Other · Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
38
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2016 · Synced Oct 23, 2026, 6:59 AM EDT
Completed Not applicable Interventional Results available

A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial

NCT02700984
View directory record Official record
Conditions
Primary Open Angle Glaucoma (POAG)
Interventions
CyPass Micro-Stent, Cataract Surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
45 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
22
States / cities
Glendale, Arizona • Fayetteville, Arkansas • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 23, 2026, 6:59 AM EDT
Completed Phase 1 Interventional Results available

Efalizumab to Treat Uveitis

NCT00280826
View directory record Official record
Conditions
Uveitis, Macular Edema
Interventions
Efalizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2011 · Synced Oct 23, 2026, 6:59 AM EDT
Active, not recruiting Phase 2 Interventional

AMX0035 in Adult Patients With Wolfram Syndrome

NCT05676034
View directory record Official record
Conditions
Wolfram Syndrome
Interventions
AMX0035
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
17 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 23, 2026, 6:59 AM EDT
Terminated Not applicable Interventional Results available

Optic Nerve Head Structural Response to IOP Elevation in Patients With Keratoconus

NCT03560609
View directory record Official record
Conditions
Keratoconus, Glaucoma
Interventions
Ophthalmodynamometer, Goldmann applanation tonometer, Pentacam, ORA, Optical Coherence Tomography (OCT)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 23, 2026, 6:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bimatoprost Ocular Insert Pharmacokinetic Study

NCT02444767
View directory record Official record
Conditions
Healthy Volunteers
Interventions
13mg Bimatoprost Ocular Insert
Drug
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Oct 23, 2026, 6:59 AM EDT
Active, not recruiting Phase 4 Interventional

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT

NCT06865144
View directory record Official record
Conditions
Primary Open Angle Glaucoma or Ocular Hypertension
Interventions
Netarsudil ophthalmic solution 0.02%, Artificial tears
Drug
Lead sponsor
East Coast Institute for Research
Network
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 23, 2026, 6:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Outcome of Sports Vision Training on Collegiate Softball Players

NCT05990036
View directory record Official record
Conditions
Athletic Performance
Interventions
Sports vision enhancement training curriculum
Other
Lead sponsor
University of the Incarnate Word
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 23, 2026, 6:59 AM EDT
Not listed No phase listed Observational

Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT

NCT05745116
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Notal Vision Home OCT
Device
Lead sponsor
Notal Vision Inc.
Industry
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • Fairfax, Virginia • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 23, 2026, 6:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution in Improving Vision in Subjects With Presbyopia

NCT02516306
View directory record Official record
Conditions
Presbyopia
Interventions
EV06 Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Encore Vision, Inc.
Industry
Eligibility
45 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Artesia, California • Mission Hills, California • Washington, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 23, 2026, 6:59 AM EDT
Completed Not applicable Interventional Results available

The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction

NCT01207752
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
Systane Balance, Optive Lubricant Eye Drops
Drug
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 23, 2026, 6:59 AM EDT
Completed No phase listed Observational

Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial Medicine

NCT05012358
View directory record Official record
Conditions
Mitochondrial Myopathies, Mitochondrial DNA Mutation, Mitochondrial Diseases, Chronic Progressive External Ophthalmoplegia With Myopathy, Kearns-Sayre Syndrome
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
15 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 23, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution

NCT05501860
View directory record Official record
Conditions
Anesthesia, Local
Interventions
AG-920, Placebo
Drug
Lead sponsor
American Genomics, LLC
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Newport Beach, California • McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 23, 2026, 6:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

NCT00804934
View directory record Official record
Conditions
Wet AMD
Interventions
Lucentis
Drug
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 23, 2026, 6:59 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 23, 2026, 6:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study for the Treatment of Ocular Chronic Graft-Versus-Host Disease (GVHD) With Amniotic Fluid Eye Drops (AFED)

NCT03298815
View directory record Official record
Conditions
Ocular Graft Versus Host Disease
Interventions
Amniotic Fluid Eye Drops (AFED), Saline Solution
Biological · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 23, 2026, 6:59 AM EDT
Recruiting Not applicable Interventional

Assessing the Impact of eSight Go At-Home Usage in Individuals With Visual Impairment

NCT07149259
View directory record Official record
Conditions
Low Vision Aids
Interventions
At Home Use
Device
Lead sponsor
Brooks Rehabilitation
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Results available

Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT01749904
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
BOL-303259-X, Timolol
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 23, 2026, 6:59 AM EDT
Completed Phase 2 Interventional

AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure

NCT01474135
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
0.25% AR-12286 / 0.004% travoprost, 0.5% AR-12286, 0.004% travoprost, 0.004% Travoprost
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Inglewood, California • Newport Beach, California • Petaluma, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 23, 2026, 6:59 AM EDT